Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition-Reference-Cited by-同舟云学术

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

Published:2017-01-16 Issue:23 Volume:36 Page:3334-3345
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Kim H S,Jung M,Kang H N,Kim H,Park C-W,Kim S-M,Shin S J,Kim S H,Kim S G,Kim E K,Yun M R,Zheng Z,Chung K Y,Greenbowe J,Ali S M,Kim T-M,Cho B C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/onc2016486.pdf

Reference52 articles.

1. Chang AE, Karnell LH, Menck HR . The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1664–1678.

2. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V . Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012; 5: 739–753.

3. Seetharamu N, Ott PA, Pavlick AC . Mucosal melanomas: a case-based review of the literature. Oncologist 2010; 15: 772–781.

4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 1. 2017. Available at:https://www.nccn.org/.

5. Gray-Schopfer V, Wellbrock C, Marais R . Melanoma biology and new targeted therapy. Nature 2007; 445: 851–857.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond;Critical Reviews in Oncology/Hematology;2024-09

2. Histopathologic, genomic, transcriptomic, and functional characteristics of eight melanocytic tumors with BRAF fusions showing stronger MAPK pathway activation compared to BRAF V600E tumors;Journal of Cutaneous Pathology;2024-08-22

3. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12

4. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23

5. Genomic Alterations in Melanocytic Tumors: A Review of Spitz Tumors, Blue Nevi, Deep Penetrating Melanocytomas and Pigmented Epithelioid Melanocytomas;Applied Sciences;2024-02-24